AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its proprietary boron chemistry platform, targeting hematologic diseases, infectious diseases, and oncology. The company's lead candidate, epetraborole, is advancing through Phase 2 studies for polycythemia vera and mycobacterium abscessus lung disease, while AN2-502998 targets Chagas disease; additional research programs focus on selective cancer inhibitors and global health infectious diseases. AN2 generates revenue through potential product commercialization and non-dilutive funding from grants, partnerships, and government contracts, while outsourcing all manufacturing to third-party providers and licensing key assets from academic and commercial partners.